OnKure Therapeutics Inc (OKUR) Total Debt to Capital

OnKure Therapeutics Inc (OKUR) maintains a strong reputation in the field of precision oncology, developing drugs tailored to specific genetic malfunctions. The technical foundation relies on the operation of modern laboratories and reserved plant capacities for mass production. A team of scientists, who efficiently manage venture capital, ensures the business's effectiveness. The shares shown on this price chart demonstrate a total debt-to-equity ratio of 0.01.

This metric compares total liabilities to net assets, determining the degree of funding dependence on borrowed funds relative to equity. For OnKure Therapeutics Inc (OKUR), amidst a fierce biotech development race and high risks of research delays, avoiding excessive leverage is critical, and the financial leverage ratio (total debt-to-equity) allows for tracking the company's resilience to market shocks.